4)특히, 이약 투여중에 수두 또는 홍역에 감염되면, 치명적인 경과에 이룰 수 있으므로 다음 주의가 필요하다
(1)이 약 투여전에 수두 또는 홍역의 병력과 예방접종의 유무를 확인한다.
(2)수두 또는 홍역의 병력이 없는 환자에 대해서는 수두 또는 홍역에의 감염을 최대한 방지하여 충분한 배려와 관찰을 한다. 감염이 의심스러운 경우와 감염된 경우에는 즉시 진찰을 받아 지도하고, 적절한 처치를 한다.
(3)수두 또는 홍역의 병력과 예방 접종을 받은 적이 있는 환자에서도 이 약 투여 중에 수두 또는 홍역이 나타날 가능성이 있으므로 유의한다.
5)전신 및 국소 코르티코스테로이드 사용으로 시력장애가 보고될 수 있다. 환자에게 시야흐림 또는 기타 시력장애와 같은 증상이 나타날 경우, 환자를 안과의사에게 보내어 백내장, 녹내장 또는 전신 및 국소 코르티코스테로이드 사용 후 보고된 중심장액맥락망막병(CSCR)과 같은 희귀질환을 포함하여 발생 가능한 원인 평가를 고려해야 한다.
Dexamethasone에 대한 Mechanism_Of_Action 정보 Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. This results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Tobramycin에 대한 Mechanism_Of_Action 정보 Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Pharmacology
Dexamethasone에 대한 Pharmacology 정보 Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions. Tobramycin에 대한 Pharmacology 정보 Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections.
Metabolism
Dexamethasone에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4) Tobramycin에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available
Protein Binding
Dexamethasone에 대한 단백결합 정보 70% Tobramycin에 대한 단백결합 정보 Not Available
Half-life
Dexamethasone에 대한 반감기 정보 36-54 hours Tobramycin에 대한 반감기 정보 Not Available
Absorption
Dexamethasone에 대한 Absorption 정보 80-90% Tobramycin에 대한 Absorption 정보 Not Available
Biotransformation
Dexamethasone에 대한 Biotransformation 정보 Hepatic. Tobramycin에 대한 Biotransformation 정보 Not Available
Toxicity
Dexamethasone에 대한 Toxicity 정보 Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri. Tobramycin에 대한 Toxicity 정보 LD50=441mg/kg (s.c. in mice)
Drug Interactions
Dexamethasone에 대한 Drug_Interactions 정보 Ambenonium The corticosteroid decreases the effect of anticholinesterasesAminoglutethimide Aminogluthetimide decreases the effect of dexamethasoneAmobarbital The barbiturate decreases the effect of the corticosteroidAnisindione The corticosteroid alters the anticoagulant effectAprepitant Aprepitant increases the effect and toxicity of dexamethasoneAprobarbital The barbiturate decreases the effect of the corticosteroidAspirin The corticosteroid decreases the effect of salicylatesButabarbital The barbiturate decreases the effect of the corticosteroidButalbital The barbiturate decreases the effect of the corticosteroidButethal The barbiturate decreases the effect of the corticosteroidDicumarol The corticosteroid alters the anticoagulant effectDihydroquinidine barbiturate The barbiturate decreases the effect of the corticosteroidEdrophonium The corticosteroid decreases the effect of anticholinesterasesEthotoin The enzyme inducer decreases the effect of the corticosteroidFosphenytoin The enzyme inducer decreases the effect of the corticosteroidHeptabarbital The barbiturate decreases the effect of the corticosteroidHexobarbital The barbiturate decreases the effect of the corticosteroidImatinib Decreases levels of imatinibMephenytoin The enzyme inducer decreases the effect of the corticosteroidMethohexital The barbiturate decreases the effect of the corticosteroidMethylphenobarbital The barbiturate decreases the effect of the corticosteroidMidodrine Increased arterial pressureNeostigmine The corticosteroid decreases the effect of anticholinesterasesPentobarbital The barbiturate decreases the effect of the corticosteroidPhenobarbital The barbiturate decreases the effect of the corticosteroidPhenytoin The enzyme inducer decreases the effect of the corticosteroidPrimidone The barbiturate decreases the effect of the corticosteroidPyridostigmine The corticosteroid decreases the effect of anticholinesterasesQuinidine barbiturate The barbiturate decreases the effect of the corticosteroidRifampin The enzyme inducer decreases the effect of the corticosteroidSecobarbital The barbiturate decreases the effect of the corticosteroidSunitinib Possible decrease in sunitinib levelsTalbutal The barbiturate decreases the effect of the corticosteroidWarfarin The corticosteroid alters the anticoagulant effectBismuth The corticosteroid decreases the effect of salicylatesAcenocoumarol The corticosteroid alters the anticoagulant effectSalicylate-magnesium The corticosteroid decreases the effect of salicylatesSalsalate The corticosteroid decreases the effect of salicylates Tobramycin에 대한 Drug_Interactions 정보 Not Available
Dexamethasone에 대한 Food Interaction 정보 Avoid alcohol.Take with food to reduce irritation.Avoid taking with grapefruit juice. Tobramycin에 대한 Food Interaction 정보 Not Available
Dexamethasone에 대한 Description 정보 An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem] Tobramycin에 대한 Description 정보 An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]
Drug Category
Dexamethasone에 대한 Drug_Category 정보 Adrenergic AgentsAnti-inflammatory AgentsAntiemeticsAntineoplastic Agents, HormonalGlucocorticoids Tobramycin에 대한 Drug_Category 정보 AminoglycosidesAnti-Bacterial Agents
Smiles String Canonical
Dexamethasone에 대한 Smiles_String_canonical 정보 CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO Tobramycin에 대한 Smiles_String_canonical 정보 NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O
Smiles String Isomeric
Dexamethasone에 대한 Smiles_String_isomeric 정보 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO Tobramycin에 대한 Smiles_String_isomeric 정보 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
InChI Identifier
Dexamethasone에 대한 InChI_Identifier 정보 InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 Tobramycin에 대한 InChI_Identifier 정보 InChI=1/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
Chemical IUPAC Name
Dexamethasone에 대한 Chemical_IUPAC_Name 정보 (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Tobramycin에 대한 Chemical_IUPAC_Name 정보 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
Drug-Induced Toxicity Related Proteins
DEXAMETHASONE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Brain-cadherin (BR-cadherin) Drug:dexamethasone Toxicity:osteoblast differentiation. [바로가기]Replated Protein:Glucocorticoid-induced leucine zipper (GILZ) Drug:dexamethasone Toxicity:apoptosis. [바로가기]Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:apoptosis. [바로가기]Replated Protein:Heme oxygenase 1 Drug:dexamethasone Toxicity:oxidative injury. [바로가기]Replated Protein:Alkaline phosphatase Drug:dexamethasone Toxicity:osteoblast differentiation. [바로가기]Replated Protein:Interleukin-6 Drug:dexamethasone Toxicity:apoptosis. [바로가기]Replated Protein:Ornithine decarboxylase Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [바로가기]Replated Protein:Aromatic-L-amino-acid decarboxylase Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [바로가기]Replated Protein:Interleukin-4 Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells. [바로가기]Replated Protein:Gastrin Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [바로가기]Replated Protein:Interleukin-4 Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells. [바로가기]Replated Protein:Cadherin-11 Drug:dexamethasone Toxicity:osteoblast differentiation. [바로가기]Replated Protein:Haptoglobin Drug:dexamethasone Toxicity:hepatic lipidosis(fatty liver). [바로가기]Replated Protein:Interferon alpha-7 Drug:dexamethasone Toxicity:apoptosis. [바로가기]Replated Protein:C-jun-amino-terminal kinase-interacting protein Drug:dexamethasone Toxicity:apoptosis of multiple myeloma cells. [바로가기]Replated Protein:Mitogen-activated protein kinase Drug:dexamethasone Toxicity:Dex-induced apoptosis. [바로가기]Replated Protein:Cadherin-4 Drug:dexamethasone Toxicity:osteoblast differentiation. [바로가기]Replated Protein:Glucose transporter 4 Drug:dexamethasone Toxicity:cushing's syndrome. [바로가기]Replated Protein:Nuclear factor NF-kappa-B Drug:dexamethasone Toxicity:pulmonary inflammation. [바로가기]Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:oxidative injury such as endotoxins and heme. [바로가기]Replated Protein:Thrombomodulin Drug:dexamethasone Toxicity:deep venous thrombosis (DVT). [바로가기]Replated Protein:Islet amyloid polypeptide Drug:dexamethasone Toxicity:marked stimulatory effect. [바로가기]TOBRAMYCIN 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Lysozyme Drug:tobramycin Toxicity:nephrotoxicity. [바로가기]Replated Protein:phospholipases C Drug:tobramycin Toxicity:aminoglycoside toxicity. [바로가기]Replated Protein:Phospholipase A Drug:tobramycin Toxicity:aminoglycoside toxicity. [바로가기]Replated Protein:Lactate dehydrogenase Drug:tobramycin Toxicity:nephrotoxicity. [바로가기]
사용자컨텐츠
항목
내용
최근정보수정일 2020-05-11
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
알림
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다.
경고
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ≥4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. DEXAMETHASONE [GGT Increase] [Composite Activity] (Score) NA (Marginal) 0 (Active) 0
[Alkaline Phosphatase Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[SGOT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[SGPT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[LDH Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[GGT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
전문/일반
